

Curriculum Vitae

PERSONAL INFORMATION

Surname, first name, degree: Leich-Zbat, Ellen, PD Dr. rer. nat.

Place/Date of birth: Ludwigshafen am Rhein/07.08.1978

Phone: 0931-31-81181 (office), 0931-31-81239 (lab)

E-mail Address: ellen.leich@uni-wuerzburg.de

EDUCATION AND TRAINING

- | | |
|-----------|--|
| 1998-1999 | Study of Chemical Engineering, Technical College, Mannheim |
| 1999-2004 | Study of Biology (Dipl.), Goethe-Universität, Frankfurt a. M. |
| 2005-2009 | Phd-student, Institute of Pathology, University of Würzburg
<i>„Characterization of Follicular Lymphoma Lacking The Hallmark Translocation $t(14;18)$ (magnacum laude)</i> |
| 2009-2013 | Postdoc and assistant lab manager, Institute of Pathology, University of Würzburg |

WORK EXPERIENCE / MAJOR POSITIONS

- | | |
|----------------|---|
| Since 2013 | Principal investigator, team leader and assistant lab manager, Institute of Pathology, University of Würzburg |
| 2017-2020 | Habilitation in the field “molecular pathology”, Institute of Pathology, University of Würzburg |
| Since May 2020 | Head of laboratory, team leader and principle investigator, Institute of Pathology, University of Würzburg |
| 18.05.2020 | Obtaining the “venia legendi” |

OTHER FUNCTIONS

- Contact person for indolent B-cell lymphoma, gene expression and pathology in the Science Work Group of the GLA
- Editorial Board Member (Cancers, Journal of Personalized Medicine (JPM))
- Grant reviewer for funding agencies (Deutsche Forschungsgemeinschaft, Swiss Cancer League, National Science Center (Poland))

- Adhoc reviewer for scientific journals (e.g. British Journal of Haematology, Haematologica, Biomolecules, Genes, Chromosomes & Cancer, OncoTargets and Therapy, HemaSphere)

PEER REVIEWED PUBLICATIONS

Total	First author	Last author	Citations	h-index
45	9 (2/9 corresponding)	5 (5/5 corresponding)	2762	28

EXTERNAL FUNDING

2013-2016 **Deutsche Forschungsgemeinschaft (DFG)**, KFO216

Characterization of the Oncogenic Signaling Network in Multiple Myeloma

367.600€

2014-2017 **Wilhelm-Sander-Stiftung**, Sandertherapieeinheit

Therapiebegleitende Identifizierung molekularer Veränderungen beim Hochrisiko-Myelom

240.000€

2018-2021 **Deutsche Krebshilfe**

Analyse der funktionellen und klinischen Bedeutung von molekularen Subgruppen des Rezeptor-Tyrosinkinase-Signaltransduktions-Netzwerks im multiplen Myelom

331.215€